Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
A Long-Term Follow-Up Study of ADVM-022 in Diabetic Macular Edema- INFINITY Extension
Sponsor: Adverum Biotechnologies, Inc.
This observational or N/A phase trial investigates Diabetic Macular Edema and Diabetic Retinopathy and is currently ongoing. Adverum Biotechnologies, Inc. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
4 versions recorded-
May 2025 — Present [monthly]
Active Not Recruiting
Status: Enrolling By Invitation → Active Not Recruiting
-
Sep 2024 — May 2025 [monthly]
Enrolling By Invitation
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation
-
Dec 2022 — Jul 2024 [monthly]
Enrolling By Invitation
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Adverum Biotechnologies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .